CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2009-03-17): Telbivudine better than lamivudine for chronic hepatitis B

Clinical

Telbivudine better than lamivudine for chronic hepatitis B

Last Updated: 2009-03-17 8:00:19 -0400 (Reuters Health)

NEW YORK (Reuters Health) - As a treatment for chronic hepatitis B, telbivudine produces a better therapeutic response than does lamivudine in both HBeAg-positive and -negative patients, according to 2-year follow-up data from the GLOBE trial.

When it became available in 1998, lamivudine revolutionized the treatment of chronic hepatitis B, note Dr. Yun-Fan Liaw, from Chang Gung University College of Medicine, Taipei, Taiwan, and colleagues. The current findings, however, suggest that the newer agent telbivudine has now displaced lamivudine as the treatment of choice.

The GLOBE trial included 921 HBeAg-positive and 446 HBeAg-negative patients who were randomized to receive telbivudine or lamivudine once daily for 104 weeks. Therapeutic response, the main outcome, was defined as a hepatitis B virus DNA level < 5 log10 copies/mL and HBeAg loss or normalization of the alanine aminotransferase level.

In HBeAg-positive patients, the treatment response rate was higher with telbivudine than with lamivudine: 63% vs. 48% (p < 0.001), according to the report in the February issue of Gastroenterology. In HBeAg-negative patients, the corresponding rates were 78% and 66% (p = 0.007).

Compared with lamivudine, treatment with telbivudine in the HBeAg-positive group was associated with higher rates of nondetectable viremia and HBeAg loss and with lower rates of viral resistance. In the HBeAg-negative group, telbivudine use also increased the odds of nondetectable viremia and was tied to less viral resistance.

In general, the two drugs had comparable side effect profiles, although telbivudine was more often linked to grade 3/4 increases in creatine kinase levels: 12.9% vs. 4.1% (p < 0.001).

Despite these findings, however, the future of telbivudine as a long-term treatment for chronic hepatitis B is uncertain, Dr. Robert J. Fontana, from the University of Michigan Medical Center, Ann Arbor, comments in a related editorial.

"The rising incidence of telbivudine-resistant hepatitis B virus will likely limit its long-term utility in the management of chronic hepatitis B virus," he writes. "Additional drugs that target other steps in the hepatitis B virus replication cycle or host immune response are needed."

Gastroenterology 2009;136:389-403,486-495.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.